Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes. To investigate the polygenetic basis of serum uric acid levels, we conducted a meta-analysis of genome-wide association scans from 14 studies totalling 28,141 participants of European descent, resulting in identification of 954 SNPs distributed across nine loci that exceeded the threshold of genome-wide significance, five of which are novel. Overall, the common variants associated with serum uric acid levels fall in the following nine regions:
Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes. To investigate the polygenetic basis of serum uric acid levels, we conducted a meta-analysis of genome-wide association scans from 14 studies totalling 28,141 participants of European descent, resulting in identification of 954 SNPs distributed across nine loci that exceeded the threshold of genome-wide significance, five of which are novel. Overall, the common variants associated with serum uric acid levels fall in the following nine regions: SLC2A9 (p = 5.2610 2201 ), ABCG2 (p = 3.1610 226 ), SLC17A1 (p = 3.0610 214 ), SLC22A11 (p = 6.7610 214 ), SLC22A12 (p = 2.0610 29 ), SLC16A9 (p = 1.1610 28 ), GCKR (p = 1.4610 29 ), LRRC16A (p = 8.5610 29 ) , and near PDZK1 (p = 2.7610 29 ). Identified variants were analyzed for gender differences. We found that the minor allele for rs734553 in SLC2A9 has greater influence in lowering uric acid levels in women and the minor allele of rs2231142 in ABCG2 elevates uric acid levels more strongly in men compared to women. To further characterize the identified variants, we analyzed their association with a panel of metabolites. rs12356193 within SLC16A9 was associated with DL-carnitine (p = 4.0610 226 ) and propionyl-L-carnitine (p = 5.0610 28 ) concentrations, which in turn were associated with serum UA levels (p = 1.4610 257 and p = 8.1610 254 , respectively), forming a triangle between SNP, metabolites, and UA levels. Taken together, these associations highlight additional pathways that are important in the regulation of serum uric acid levels and point toward novel potential targets for pharmacological intervention to prevent or treat hyperuricemia. In addition, these findings strongly support the hypothesis that transport proteins are key in regulating serum uric acid levels.
Introduction
Uric acid (UA) is the final catabolic, heterocyclic purine derivative resulting from the oxidation of purines in humans. Due to the loss of hepatic uricase activity during human evolution, UA is excreted as such and is not further metabolized into carbon dioxide and ammonia. A major mechanism underlying hyperuricemia is impaired renal excretion of urate. Most notably, UA is causally involved in the pathogenesis of gouty arthritis that results from deposition of monosodium urate crystals in the joints [1] . Increased UA concentrations have been implicated in cardiovascular disease for more than five decades [2] . In addition, elevated urate is associated with obesity, blood pressure and insulin resistance, and consequently with the metabolic syndrome and type 2 diabetes [2, 3] . However, UA also has a positive role as an antioxidant, and is correlated with longevity in mammals [4] . Thus, human physiology is especially sensitive to the precise range of UA levels.
Besides environmental factors, there is evidence for a strong genetic influence upon serum UA concentrations, with heritability estimates of up to 73% [5] . Recently, genome-wide association (GWA) studies have identified single nucleotide polymorphisms (SNPs) in the SLC2A9 gene (solute carrier family 2, member 9 gene), a putative glucose transporter, which are strongly associated with serum UA concentrations and gout [6] [7] [8] [9] . This novel gene locus functions as a high-capacity urate transporter in humans [8, 10] . This emphasises the power of GWA studies in expanding our understanding at the molecular level of disease mechanisms and in pointing to innovative therapeutic strategies.
The power of GWA studies to detect common variants with modest effects directly depends on the size of the study group. Therefore, the present study sought to detect novel genetic variants related to serum UA levels by conducting a meta-analysis of GWA findings from 14 studies (BRIGHT, CoLaus, CROATIA, Health 2000, KORA F3, KORA S4, ORCADES, PROCARDIS, NSPHS, SardiNIA, SHIP, SSAGA, MICROS, and TwinsUK) totalling 28,141 participants. In addition, the meta-analysis was performed independently on sex specific GWA results to address the pronounced gender differences in the regulation of UA concentrations that have previously been reported [1, 6] . Identified variants were further analyzed for association with metabolite profiles.
Results
The sample size and participant characteristics for each participating study are shown in Table S1 . Meta-analysis of
Author Summary
Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes. The regulation of serum uric acid levels is under a strong genetic control. This study describes the first meta-analysis of genome-wide association scans from 14 studies totalling 28,141 participants of European descent. We show that common DNA variants at nine different loci are associated with uric acid concentrations, five of which are novel. These variants are located within the genes coding for organic anion transporter 4 (SLC22A11), monocarboxylic acid transporter 9 (SLC16A9), glucokinase regulatory protein (GCKR), Carmil (LRRC16A), and near PDZ domaincontaining 1 (PDZK1). Gender-specific effects are shown for variants within the recently identified genes coding for glucose transporter 9 (SLC2A9) and the ATP-binding cassette transporter (ABCG2). Based on screening of 163 metabolites, we show an association of one of the identified variants within SLC16A9 with DL-carnitine and propionyl-L-carnitine. Moreover, DL-carnitine and propionyl-L-carnitine were strongly correlated with serum UA levels, forming a triangle between SNP, metabolites and UA levels. Taken together, these associations highlight pathways that are important in the regulation of serum uric acid levels and point toward novel potential targets for pharmacological intervention to prevent or treat hyperuricemia.
GWA data of 28,141 individuals of European ancestry yielded 954 SNPs (full list is provided in Table S4 ) that exceeded the genomewide significance threshold of 5610 28 ( Figure 1A ). Those SNPs cluster around nine loci ( ). The first, SLC2A9, was identified in previous GWA scans ( Figure 2C ) [6] [7] [8] [9] . A total of 788 SNPs reached the genome-wide significance threshold at the SLC2A9 locus. The strongest associated marker was the intronic SNP rs734553 (p = 5.2610 2201 , Table 1 ), which is in high linkage disequilibrium (r 2 = 0.88) with the missense mutation rs16890979 previously described [11] . The second locus was on chromosome 4q22, harbouring the ABCG2 gene ( Figure 2D ). In accordance with previous results, the strongest observed association was at rs2231142 (p = 3.1610
226
, Table 1 ), a coding SNP leading to a glutamine-tolysine amino acid change at position 141 [11] . The third previously implicated locus influencing UA levels was on chromosome 6p23-p21.3, which contains the SLC17A3 gene ( Figure 2F ) [11] . The top associated marker was SNP rs1183201 (p = 3.0610
214
, Table 1 ), intronic of SLC17A1, but the association signal encompassed a larger region including the SLC17A1, SLC17A3, SLC17A4 genes and downstream to HIST1H4C, in agreement with the linkage disequilibrium at this locus. SNP rs1183201 is in high linkage disequilibrium (r 2 = 0.97) with rs1165205, a SNP intronic of SLC17A3 gene identified by a previous GWA scan [11] .
Among the novel loci identified, the strongest was on chromosome 11q13. One locus was localized upstream and within the SLC22A11 gene, and represented by SNP rs17300741 (p = 6.7610 214 , Table 1 , Figure 2H ). The second signal was SNP rs505802 (p = 2.0610 29 ), representative of all associated markers falling within and downstream the extensively studied SLC22A12 gene coding for URAT1 ( Figure 2I ). The p-value plot as well as the LD block structure (r 2 = 0.09) suggested two nearby but independently associated regions, which was verified in multiple regression analysis (Table S5) .
The second novel region was on chromosome 2p23.3-p23.2 ( Figure 2B ). The most significant SNP in this region was SNP rs780094 (p = 1.4610
29
), intronic of GCKR, a glucokinase regulator protein recently associated with several quantitative traits including the regulation of triglycerides levels [12] . We also identified genomewide significant association on chromosome 1q21 (Figure 2A ). The top ranking SNP in this region was rs12129861 (p = 2.7610 29 , Table 1 ), located 2 kb upstream of PDZK1 coding for PDZ domaincontaining 1 reported to interact with URAT1 [13] . The fourth newly detected region was found on chromosome 6p22.2 ( Figure 2E ), where the association signal spans two genes, LRRC16A and SCGN, within one highly preserved LD block. The strongest p-value was observed for the SNP rs742132, located within an intron of LRRC16A (p = 8.5610
, Table 1 ). Independence of the LRRC16A and the SLC17A1 loci (r 2 = 0.07) was verified in multiple regression analysis. P-values and effect estimates only slightly changed between single SNP analysis and multiple regression analysis (Table S5 ). Finally, we also observed some evidence of association on chromosome 10q21.3 ( Figure 2G ). One SNP within SLC16A9, rs12356193, reached genome-wide significance (p = 1.1610
28
). However, there were several additional SNPs within this gene with borderline significance, supporting the hypothesis that this locus may be a true signal rather than a false positive result.
Sex-Stratified Meta-Analysis Identifies Male and Female Specific Variants
We have also performed a meta-analysis of sex specific GWA results using all 14 studies (12,328 males, 15,813 females).
Although the results did not show any additional genome-wide significant locus ( Figure 1B and 1C), we were able to query which of the aforementioned SNPs have sex-specific effects on serum UA levels ( Table 2 ). For the SLC2A9 gene, we found that in males the top ranking SNP was still rs734553 (p = 1.1610 241 ), while for women it was the nearby intronic SNP rs12498742 (p = 2.4610 2196 ). Supporting previously reported results, we found for both markers that the effect size of the minor allele observed in women was twice the effect size observed in men (p,3.8610 217 , Table 2 ) [6] . The minor allele of rs2231142 in the ABCG2 gene showed a greater effect size in men compared to women (p = 0.01, Table 2 ). Similar, the effect size of the most significant SNP for males in the ABCG2 gene locus, rs2199936, was greater in men compared to women (p = 0.008, Table 2 ). The effect sizes of the other SNPs were comparable in men and women ( Table 2 ).
Association of Identified Variants with Metabolite Profiles
To further characterize the identified variants, we analyzed their association with a panel of 163 metabolites measured in the KORA F4 survey. After correction for multiple testing, one SNP within SLC16A9, rs12356193, was associated with DL-carnitine concentrations (b = 23.58, p = 4.0610
226
), which in turn were associated with serum UA levels (b = 0.06, p = 1.4610 257 ). In addition, this SNP was associated with propionyl-L-carnitine (b = 20.06, p = 5.0610 28 ). Similar to DL-carnitine, propionyl-Lcarnitine concentrations were also strongly associated with serum UA levels (b = 1.78, p = 8.1610
254 ), forming a triangle between SNP, metabolites and UA levels. None of the other SNPs were significantly associated with the measured metabolites.
Discussion
Based on meta-analysis of GWA studies including 28,141 individuals, we have mapped 5 novel loci and confirmed 4 previously implicated loci that influence serum UA levels. Altogether, these associations highlight biological pathways that are important in the regulation of urate concentrations and may point to novel targets for pharmacological interventions to prevent or treat hyperuricemia.
A genome-wide significant p-value was observed for one SNP within SLC16A9 gene locus, coding for monocarboxylic acid transporter 9 (MCT9). This is a member of the monocarboxylate co-transporter family that has been demonstrated to catalyze transport of monocarboxylic acids across cell membranes [14] . MCT9 is expressed in various tissues including the kidney [15] . As other sodium monocarboxylate transporters have been found to influence urate in knockout models this MCT9 isoform might be a sodium-dependent transporter in the kidney. The second newly identified locus was GCKR (glucokinase regulatory protein) a regulator of glucokinase, the first glycolytic enzyme which serves as a glucose sensor, responsible for glucose phosphorylation in the liver. Recently, GWA studies for type 2 diabetes identified the same rs780094 SNP as a potential marker for modulation of triglyceride levels [16] . Meanwhile, GCKR polymorphisms were also shown to be associated with metabolic traits like fasting glucose and, modestly, type 2 diabetes [12, 17, 18] . Several potential mechanisms have been proposed to link serum UA concentrations with metabolic traits. Exogenous insulin decreases renal sodium and urate excretion [19] . Furthermore, renal clearance of UA is inversely related to the degree of insulin resistance [20] . Finally, insulin resistance is thought to be accompanied by impaired oxidative phosphorylation in hepatic mitochondria, leading to increased concentrations of co-enzyme A esters and thus to increased systemic adenosine concentrations Shown are the gender-specific loci for the most significant SNP at the nine associated loci. Positions are given according to NCBI Build 36. Effect estimates result from additive linear regression on Z-scores of uric acid concentrations when only males (or females) were considered for the analysis. P-values have been calculated using weighting by the inverse variance. The effect allele is the allele to which the beta (effect) estimate refers. When different from the main meta-analysis, the most associated marker in males (females) is also listed. doi:10.1371/journal.pgen.1000504.t002 [21] . Increased adenosine, in turn, may result in renal retention of sodium, urate, and water [21, 22] . This provides a putative mechanism for hyperuricaemia via both the break down of adenosine to urate and increased renal urate retention [21, 22] . We also found evidence for association in a region containing two genes, LRRC16A and SCGN. The strongest association was located within LRRC16A coding for CARMIL. This large protein is most abundant in kidney and epithelial tissues and serves as an inhibitor of the heterodimeric actin capping protein (CP), an essential element of the actin cytoskeleton which binds to the barbed ends of actin filaments and regulates their polymerization [23] . The multiple biochemical functions associated with CAR-MIL raise many possibilities for its mechanism of action in cells, but the relation of CARMIL to UA concentration is thus far unclear. The nearby SCGN is coding for Secretagogin, a calciumbinding protein selectively expressed in neuroendocrine tissue and pancreatic beta-cells. The function of Secretagogin is unknown, but it has been suggested to influence calcium influx and insulin secretion [24] .
We also demonstrated association of SNPs in SLC22A11 and SLC22A12 with UA concentrations. SLC22A12 encodes the extensively studied URAT1, a member of the organic anion transporter (OAT) family [25] . URAT1, a well known candidate gene for UA accumulation/transport, mediates the non-voltagedependent exchange of urate for several organic anions [1] . SLC22A11 codes for OAT4, an OAT isoform which, like URAT1, is localized at the apical membrane of the proximal tubules. OAT4 serves as an organic anion-dicarboxylate exchanger, which mediates urate transport across the apical membrane of kidney [26, 27] . In combination with these findings, we also identified genome-wide significant association of SNPs in and upstream of PDZK1, coding for PDZ domain containing 1, a scaffolding protein reported to interact with OAT4, URAT1 and NTP1 (SLC17A1) via their C-terminal PDZ motifs [13, 28] . It has been proposed that the PDZ scaffold may form a bidirectional transport system by linking URAT1 (reabsorption) and NPT1 (secretion) leading to a functional complex responsible for the balanced urate transport regulation at the apical membrane of renal proximal tubules [1, 28] .
In accordance with previous genome-wide studies, the strongest effect on serum UA concentrations was detected for SLC2A9, [6] [7] [8] [9] coding for GLUT9, which has been shown to be strongly associated with hyperuricemia and gout and to serve as a highcapacity urate transporter in humans [8, 10] . Additional confirmed loci include ABCG2 and SLC17A1 [11] . ABCG2 is a member of the ATP-binding cassette (ABC) superfamily of membrane transporters, while the SLC17A1 locus, located directly downstream of the recently identified SLC17A3 locus (NPT4), encodes NPT1 (renal sodium phosphate transport protein 1). The human NPT1 is localized at the apical membrane of renal proximal tubules and serves as a voltage-driven UA transporter in model systems [28] .
Although several of the SNPs associated with uric acid concentrations in this meta-analysis are located within genes that are plausible candidates for influencing uric acid concentrations, our association approach is not able to identify underlying genes or mechanisms in the regions of association signals. Therefore, other genes might be responsible for the observed associations and functional studies are warranted to identify the causal variants and provide insights in the underlying biological mechanisms.
Pronounced gender differences in the regulation of serum UA concentrations have been reported for both humans and animals [1, 6] . In line with our previous findings, [6] the strongest genderspecific effect was observed for the minor allele of rs734553 (SLC2A9), resulting in a 2-fold larger effect size on serum UA concentrations in women compared to men. For ABCG2, the effect of the minor allele of rs2231142 demonstrated a larger effect on UA concentrations in men compared to women. For the other loci, effect sizes did not significantly differ by gender.
The rapidly evolving field of metabolomics aims at a comprehensive measurement of endogenous metabolites in a cell or body fluid [29] . Based on screening of 163 metabolites, we have observed an association of one of the identified variants, rs12356193 within SLC16A9, with DL-carnitine and propionyl-L-carnitine. Moreover, DL-carnitine and propionyl-L-carnitine were strongly correlated with serum UA levels, forming a triangle between SNP, metabolites and UA levels. Carnitine is acquired from diet and endogenous biosynthesis. Its primary function is in the transport of long chain fatty acids. After strenuous physical exercise, both acylcarnitine and UA levels increase in the serum of healthy humans [30] . In spontaneously hypertensive rats, Lcarnitine decreases serum UA levels and the age-dependent rise in serum UA [31, 32] . Kidneys absorb 95% of carnitine from the glomerular filtrate via an active Na + -dependent transport mechanism [33] . Impairment of this reabsorptive function can lead to carnitine deficiency, in which hyperuricemia may be present because carnitine competes for renal tubular excretion [34] . Although experimental data are few, currently available data suggest that urinary acylcarnitine, which reflects the balance between dietary intake of carnitine and renal excretion, may be linked to serum UA via oxidative stress pathways [35] . Given that palmitoyl carnitine inhibits binding of Ca 2+ channel ligands to rat brain cortical membranes and to inhibit voltage-activated Ca 2+ channel currents, acylcarnitines may also have direct influences on MCT9 [36] .
Overall, serum UA concentrations are mainly determined by the balance between urate production and renal excretion. We have identified nine loci that are associated with serum UA levels and six of them harbor genes that code for renal transport proteins. Most notably, five of these transport proteins belong to the family-and moreover, to one phylogenetic cluster within this family [37] . These findings strongly support the hypothesis that genetic variation in urate transport proteins are the key influences upon regulation of serum UA levels in humans.
Materials and Methods

Study Participants
The present meta-analysis combined data from 14 (Table S1 ). Approval was obtained by local ethic committees for all studies and informed consent was given from the study participants. A detailed individual description of study designs is provided in Text S1.
Genome-Wide Genotyping and Imputation
Six different platforms/arrays were used for genotyping: the Affymetrix 500 K GeneChip array (4 cohorts, n = 13,103), the Affymetrix 6.0 GeneChip array (2 cohorts, n = 5,901), Illumina HumanHap 300 (5 cohorts, n = 3,609), Illumina Human 610 K Beadchip (1 cohort, n = 2,212), Illumina HumanHap 300-Duo (1 cohort, n = 2,113), and Illumina Human 1 M beadchip (1 cohort, n = 1,203). Imputation of allele dosage of SNPs typed in the HapMap CEU population was performed using either MACH [38] or IMPUTE [39] with parameters and pre-imputation filters as specified in Table S2 . All SNPs with a minor allele frequency ,0.01 were excluded from analysis. SNPs were also excluded if the cohort-specific imputation quality as assessed by r2.hat (MACH) or .info (IMPUTE) metrics was ,0.30 or ,0.40, respectively. In total, up to 2,493,963 genotyped or imputed autosomal SNPs were analyzed. 
Uric Acid Measurements
Metabolite Measurements
Metabolomic analyses were conducted in 2020 randomly selected participants (ages 32-81 years) of the KORA F4 survey, a follow-up survey of KORA S4. Genotype information was available for 1814 of these participants. Fasting blood samples were collected in 2006-2008. Blood was drawn into serum gel tube in the morning between 8 and 10 am. The tube was gently inverted two times, followed by 30 minutes resting at room temperature to obtain complete coagulation, and finally centrifugation of blood was performed at 2750 g, 15uC for 10 minutes for serum collection. Serum was aliquoted and kept at 4uC for a maximum of 6 hours, after which it was frozen at 280uC until analyses. Liquid handling of serum samples (10 ml) was performed with Hamilton Star (Hamilton Bonaduz AG, Bonaduz, Switzerland) robot and prepared for quantification with AbsoluteIDQ kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). Sample analyses were done on API4000 Q TRAP LC/MS/MS System (Applied Biosystems, Darmstadt, Germany) equipped with Schimadzu Prominence LC20AD pump and SIL-20AC auto sampler. The complete analytical process (e.g. the targeted metabolite concentration) was performed using the MetIQ software package, which is an integral part of the AbsoluteIDQ Kit. A total of 163 metabolites were measured. The metabolomics dataset contains 14 amino acids, one sugar, 41 acylcarnitines, 15 sphingolipids, and 92 glycerophospholipids.
Statistical Analysis
GWA scans were made using an additive genetic model on Zscores, calculated by adjusting serum UA levels for age and sex using linear regression and standardizing residuals. In sex-specific association testing Z-scores were calculated in each stratum separately. Study-specific results of the most significant SNP at each locus are presented in Table S3 . The results from all 14 GWA scans were combined into a fixed-effects meta-analysis with inverse variance weighting, using the METAL package (www.sph. umich.edu/csg/abecasis/metal). The individual studies were corrected for residual inflation of the test statistic using genomic control methods for genotyped and imputed SNPs combined [40] . For the overall meta-analysis, the inflation factor was 1.028, no further correction was applied. Quantile-quantile plots of the association results are shown in Figure S1 , study-specific quantilequantile plots are illustrated in Figure S2 and S3. Associations were considered genome-wide significant below p = 5610
28
, which corresponds to a Bonferroni correction for the estimated one million independent common variant tests in the human genome of European individuals [41] . We also tested whether the effect estimate resulting from the gender-specific fixed effect metaanalysis differed significantly between men and women by applying a t-test comparing effect and standard error estimates in men with the effect and standard error estimates in women. Genome-wide significant SNPs were tested for independent associations, by including all SNPs in a multiple regression model, and then performing inverse variance weighted meta-analysis, across all cohorts (except for Health 2000), of the coefficient for each SNP. The analysis of metabolites was performed using the same linear regression adjusted by sex and gender as in the genome-wide scan. To specify the dependency of uric acid on metabolite concentration, a univariate regression model without further transformation or adjustment was used. The multiple regression and metabolite analysis were performed using either posterior expected allele dosages, or on best-guess imputed genotypes, with the statistical analysis software R.
Accession Numbers
The OMIM (http://www.ncbi.nlm.nih.gov/OMIM) accession numbers for genes mentioned in this article are PDZK1 (603831), GCKR (600842), SLC2A9 (606142), ABCG2 (603756), LRRC16A (609593), SLC17A1 (182308), SLC22A11 (607097), and SLC22A12 (607096). The HGNC (http://www.gene.ucl.ac.uk) accession number for SLC16A9 is 23520. Figure S1 Quantile-quantile plots of association results. Metaanalysis was performed using sample-size weighted Z-scores after cohort-specific genomic control. Shown are expected p-values plotted against observed p-values resulting from meta-analysis based on all subjects (1st row), only males (2nd row) and only females (3rd row) for all analysed SNPs (left column) and for all analysed SNPs excluding the SLC2A9 region (GLUT9, right column). 
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